December 8, 2015
Eli Lilly Alzheimer’s Drug Development Veteran Rounds Out Leadership Team for Phase 3 Ready AGB101 Baltimore, MD, December 8, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced the appointment of Alzheimer’s drug…
November 24, 2015
Baltimore, MD, November 24, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present on a panel at the Future of Innovation in Medicine Conference: Incentives for New Medical…
November 12, 2015
Baltimore, MD, November 11, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present as a “Top Project to Watch: Most Licensable Products in Neuroscience” at the Informa Therapeutic…
November 6, 2015
AGB101 formulation suitable for use in the upcoming HOPE4MCI Phase 3 clinical trial to slow the progression of aMCI, the symptomatic pre-dementia stage of Alzheimer’s disease Baltimore, MD, November 6, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for…
October 22, 2015
Scientific Leadership to Focus on Upcoming HOPE4MCI Phase 3 Trial and Proprietary AGB101 Formulation Baltimore, MD, October 22, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present at the…
October 6, 2015
BALTIMORE, MD, October 6, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present at the BIO Investor Forum. The conference will be held October 20 to 21 at…
September 15, 2015
Public-private partnership will support first and only trial to reduce hippocampal overactivity during aMCI, the pre-dementia stage of Alzheimer’s disease BALTIMORE, MD, September 15, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today…
March 11, 2015
First and only clinical trial to reduce hippocampal overactivity during aMCI, the pre-dementia stage of Alzheimer’s disease Restored brain function to pre-disease levels and significantly improved memory BALTIMORE, MD March 11, 2015 /PR Newswire/ — AgeneBio, a pharmaceutical company developing…
January 28, 2015
Phase 3-ready AGB101 designed to address aMCI, the pre-dementia stage of Alzheimer’s disease BALTIMORE, MD January 28, 2015 /PR Newswire/ — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling amnestic mild cognitive impairment (aMCI), the pre-dementia stage…
January 7, 2015
BALTIMORE, MD January 7, 2015 /PR Newswire/ — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling amnestic mild cognitive impairment (aMCI), the pre-dementia phase of Alzheimer’s disease, and other neurological and psychiatric diseases, today announced that the…